Neurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic Indications
Authors:
- Carson M. QuinnCQCarson M. Quinn
- Prashanth RajarajanPRPrashanth Rajarajan
- Alexander J. GillAGAlexander J. Gill
- Hannah KopinskyHKHannah Kopinsky
- Andrew B. WolfAWAndrew B. Wolf
- Celeste Soares de CamargoCCCeleste Soares de Camargo
- Jessica LambJLJessica Lamb
- Tamar E. BaconTBTamar E. Bacon
- Joseph C. MurrayJMJoseph C. Murray
- John C. ProbascoJPJohn C. Probasco
- Kristin M. GalettaKGKristin M. Galetta
- Daniel KantorDKDaniel Kantor
- 10 December 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (11) , e210003
Abstract
Immune checkpoint inhibitors (ICIs) are increasingly used against various cancers but are associated with immune-related adverse events (irAEs). Risk of irAEs may be higher in patients with certain preexisting autoimmune diseases, and these patients may also experience exacerbation of the underlying autoimmune disease following ICI initiation. People with multiple sclerosis (MS) have mostly been excluded from clinical trials of ICIs, so data on the safety of ICIs in MS are limited. This study aims to assess the rate of MS activity, as well as neurologic and nonneurologic irAEs in persons with MS treated with ICIs for cancer. Participating sites were invited to this retrospective observational study through the Medical Partnership 4 MS+ listserv. Seven large academic centers participated in the study, each conducting a systematic search of their electronic medical record system for patients with MS and history of ICI treatment. The participating neurologist reviewed each chart individually to ensure the inclusion criteria were met. Demographics and data on MS and cancer history, treatments, and outcomes were abstracted from patient charts using a structured instrument. We identified 66 people with MS (median age 66 years, 73% female, 68% not on disease-modifying therapy for MS) who were treated with ICIs for lung cancer (35%), melanoma (21%), or another oncologic indication. During post-ICI follow-up (median: 11.7 months, range 0.2-106.3 months), 2 patients (3%) had relapse or MRI activity, 3 (5%) had neurologic irAEs, and 21 (32%) had nonneurologic irAEs. At the last follow-up, 25 (38%) participants had partial or complete remission of their cancer, while 35 (53%) were deceased. In this multi-institutional systematic retrospective study of predominantly older patients with MS, most of whom were not on disease-modifying therapy, MS activity and neurologic irAEs following ICI treatment were rare. These data suggest that preexisting MS should not preclude the use of ICIs for cancer in older patients, but the results may not be generalizable to younger patients with active MS. Prospective studies of ICI safety that enroll younger patients with MS are needed.Keywords
All Related Versions
This publication has 20 references indexed in Scilit:
- Immune Checkpoint Inhibitors in Patients with Pre-existing Neurologic Autoimmune DisordersCurrent Neurology and Neuroscience Reports, 2023
- Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trialThe Lancet Neurology, 2023
- Immune checkpoint inhibition in patients with inactive pre-existing neuromuscular autoimmune diseasesJournal of the Neurological Sciences, 2022
- Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing–remitting multiple sclerosis patientsJournal of Neurology, 2021
- Neurotoxicities associated with immune checkpoint inhibitor therapyJournal of Neuro-Oncology, 2021
- A longitudinal study of symptom botheration in Multiple Sclerosis.Multiple Sclerosis and Related Disorders, 2020
- Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory diseaseEuropean Journal of Cancer, 2018
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteriaThe Lancet Neurology, 2018
- Immune-Related Adverse Events Associated with Immune Checkpoint BlockadeNew England Journal of Medicine, 2018
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studiesInternational Journal of Surgery, 2014